Michael Yee
Stock Analyst
(3.92)
# 2,939
Out of 4,648 analysts
74
Total ratings
45.1%
Success rate
13.12%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $27.21 | +65.38% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $53.54 | +2.73% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $21.86 | +60.11% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $26.95 | +48.42% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $431.57 | -10.79% | 4 | Jul 17, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $1.4 → $10 | $2.29 | +336.68% | 3 | Mar 27, 2024 | |
| CRGX CARGO Therapeutics | Maintains: Buy | $28 → $32 | $21.20 | +50.94% | 2 | Mar 22, 2024 | |
| IMRX Immuneering | Downgrades: Hold | $16 → $3 | $1.86 | +61.29% | 2 | Mar 15, 2024 | |
| BEAM Beam Therapeutics | Downgrades: Hold | $75 → $30 | $24.36 | +23.15% | 2 | Dec 8, 2023 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $8 → $18 | $1.49 | +1,108.05% | 3 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 → $1 | $0.60 | +65.37% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $27.67 | -27.72% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $310 | $316.91 | -2.18% | 4 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 | $3.90 | -23.08% | 2 | Jul 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $9.48 | +691.14% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $340 | $472.80 | -28.09% | 3 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $350 | $173.52 | +101.71% | 4 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $2.15 | +1,295.35% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $31.17 | +108.53% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $45 | $0.33 | +13,729.13% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $2.00 | +1,400.00% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $16.46 | +82.26% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $16.98 | +606.71% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $18.24 | +311.18% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $15.55 | +92.93% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $11.93 | +545.43% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $89.84 | - | 3 | Jan 26, 2018 |
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $27.21
Upside: +65.38%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $53.54
Upside: +2.73%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $21.86
Upside: +60.11%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $26.95
Upside: +48.42%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $431.57
Upside: -10.79%
Nuvation Bio
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.29
Upside: +336.68%
CARGO Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $28 → $32
Current: $21.20
Upside: +50.94%
Immuneering
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $1.86
Upside: +61.29%
Beam Therapeutics
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $24.36
Upside: +23.15%
ALX Oncology Holdings
Dec 8, 2023
Upgrades: Buy
Price Target: $8 → $18
Current: $1.49
Upside: +1,108.05%
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $0.60
Upside: +65.37%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $27.67
Upside: -27.72%
Oct 12, 2023
Reiterates: Buy
Price Target: $310
Current: $316.91
Upside: -2.18%
Jul 24, 2023
Downgrades: Hold
Price Target: $3
Current: $3.90
Upside: -23.08%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $9.48
Upside: +691.14%
Dec 19, 2022
Downgrades: Hold
Price Target: $340
Current: $472.80
Upside: -28.09%
Nov 30, 2022
Maintains: Buy
Price Target: $325 → $350
Current: $173.52
Upside: +101.71%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $2.15
Upside: +1,295.35%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $31.17
Upside: +108.53%
Mar 2, 2021
Downgrades: Hold
Price Target: $75 → $45
Current: $0.33
Upside: +13,729.13%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $2.00
Upside: +1,400.00%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $16.46
Upside: +82.26%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $16.98
Upside: +606.71%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $18.24
Upside: +311.18%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $15.55
Upside: +92.93%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $11.93
Upside: +545.43%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $89.84
Upside: -